OUR INVESTMENT CASE

We are a leading provider of laboratory services to Blue Chip Pharma, NHS & Private Hospitals.

Our core business produces strong EBITDA growth and we are centrally placed to capture an unprecedented COVID-19 testing opportunity which is already contributing significant revenue growth and cash flow.

Our move to AIM is expected to accelerate our growth plans, scale up our COVID-19 testing service and allow us to take advantage of attractive M&A opportunities.

Read more at Source BioScience

AT A GLANCE

RNS
Announcements

Reports & Presentations

Board of
Directors

Shareholder
Information

RNS Announcements

Stay up to date with the latest RNS Announcements from SourceBio

Subscribe to alerts
SBI.L
SOURCEBIO INTERNATIONAL PLC ORD
LSE
219.00 GBp
11
4.78%

SourceBio – 2020 Investor Video

Watch Now

Source BioScience Limited is an international provider of integrated state of the art Laboratory Services and Products. Headquartered in the UK, with sites in Cambridge, Rochdale, Ireland and San Diego, USA.

Source BioScience are leaders in conventional and next generation sequencing, gene expression and genotyping services as well as histopathology services, screening and reference laboratory diagnostic testing for cancer and other diseases. Our GMP compliant laboratories support an extensive range of equipment for analytical and physical chemistry and microbiology.

Continue reading…

A word from our CEO

“We are delighted by the strong support we’ve received from institutional investors. Our IPO on AIM allows us to significantly increase our COVID-19 testing capacity, accelerate earnings growth in our core business and execute on potential M&A opportunities. It’s an exciting time for our business and we look forward to executing on our ambitious growth plans and delivering value to our shareholders.”

Jay LeCoque

Executive Chairman, SourceBio International